{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:30:41Z","timestamp":1788582641999,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2014\/27198-8"],"award-info":[{"award-number":["2014\/27198-8"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fabry disease is a rare X-linked inherited disorder caused by deficiency of \u03b1-Galactosidase A. Hundreds of mutations and non-coding haplotypes in the <jats:italic>GLA<\/jats:italic> gene have been described; however, many are variants of unknown significance, prompting doubts about the diagnosis and treatment. The \u03b1-Galactosidase A enzymatic activity in dried blood spot (DBS) samples are widely used for screening purposes; however, even when values below the normal are found, new tests are required to confirm the diagnosis. Here we describe an analysis of <jats:italic>GLA<\/jats:italic> variants and their correlation with DBS \u03b1-Galactosidase A enzymatic activity in a large Brazilian population with Fabry disease symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analyzed <jats:italic>GLA<\/jats:italic> variants by DNA sequencing of 803 male patients with suspected Fabry disease or belonging to high-risk populations; in 179 individuals, 58 different exonic variants were detected. From these, 50 are variants described as pathogenic and eight described as variants of unknown significance. The other individuals presented complex non-coding haplotypes or had no variants. Interestingly, the enzymatic activity in DBS was different among pathogenic variants and the other genotypes, including variants of unknown significance; the first presented mean of 12% of residual activity, while the others presented levels above 70% of the activity found in healthy controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The activity of \u03b1-Galactosidase A in DBS was markedly reduced in males with known pathogenic variants when compared with subjects presenting variants of unknown significance, non-coding haplotypes, or without variants, indicating a possible non-pathogenic potential of these latter genotypes. These findings bring a better understanding about the biochemical results of \u03b1-Galactosidase A in DBS samples, as well as the possible non-pathogenic potential of non-coding haplotypes and variants of unknown significance in <jats:italic>GLA<\/jats:italic> gene. These results certainly will help clinicians to decide about the treatment of patients carrying variants in the gene causing this rare but life-threatening disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-019-1274-3","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T18:03:15Z","timestamp":1580320995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Correlation between GLA variants and alpha-Galactosidase A profile in dried blood spot: an observational study in Brazilian patients"],"prefix":"10.1186","volume":"15","author":[{"given":"Patr\u00edcia","family":"Varela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianna","family":"Mastroianni Kirsztajn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana L.","family":"Motta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renan P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauro T.","family":"Tura\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrique L. F.","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caio P.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"Nicolicht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryana","family":"Mara Marins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana G.","family":"Pessoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion C.","family":"Braga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e2nia","family":"D\u2019Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o B.","family":"Pesquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"issue":"23-24","key":"1274_CR1","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","volume":"411","author":"Christiane Auray-Blais","year":"2010","unstructured":"Auray-Blais C, Ntwari A, Clarke JTR, Warnock DG, Oliveira JP, Young SP, Millington DS, Bichet DG, Sirrs S, West ML, Casey R, Hwu WL, Keutzer J, Zhang K, Gagnon, R. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin Chim Acta 2010. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.cca.2010.07.038.","journal-title":"Clinica Chimica Acta"},{"key":"1274_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","volume":"414","author":"Michel Boutin","year":"2012","unstructured":"Boutin M, Gagnon R, Lavoie P, Auray-Blais C. LC-MS\/MS analysis of plasma lyso-Gb3 in Fabry disease. Clin Chim Acta 2012. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.cca.2012.09.026.","journal-title":"Clinica Chimica Acta"},{"issue":"1-2","key":"1274_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","volume":"344","author":"Rima El-Abassi","year":"2014","unstructured":"El-Abassi R, Singhal D, England JD. Fabry's disease. J Neurol Sci 2014. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.jns.2014.06.029.","journal-title":"Journal of the Neurological Sciences"},{"key":"1274_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1750-1172-5-30","volume":"22","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;22:5\u201330. https:\/\/doi.org\/10.1186\/1750-1172-5-30.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1274_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/ndt\/gfs526","volume":"28","author":"Wim Terryn","year":"2012","unstructured":"Terryn W, Cochat P, Froissart R, Ortiz A, Pirson Y, Poppe B, Serra A, Van Biesen W, Vanholder R, Wanner C. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European renal best practice. Nephrol Dial Transplant 2013. https:\/\/doi.org\/https:\/\/doi.org\/10.1093\/ndt\/gfs526.","journal-title":"Nephrology Dialysis Transplantation"},{"key":"1274_CR6","doi-asserted-by":"publisher","unstructured":"Oliveira JP, Ferreira S. Multiple phenotypic domains of Fabry disease and their relevance for establishing genotype\u2013 phenotype correlations. Appl Clin Genet. 2019. https:\/\/doi.org\/. https:\/\/doi.org\/10.2147\/TACG.S146022.","DOI":"10.2147\/TACG.S146022"},{"issue":"12","key":"1274_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/gim.2016.55","volume":"18","author":"Raphael Schiffmann","year":"2016","unstructured":"Schiffmann R, Fuller M, Clarke LA, Aerts JM. Is it Fabry disease? Genet Med 2016. https:\/\/doi.org\/https:\/\/doi.org\/10.1038\/gim.2016.55.","journal-title":"Genetics in Medicine"},{"key":"1274_CR8","doi-asserted-by":"publisher","unstructured":"Caudron E, Prognon P, Germain DP. Enzymatic diagnosis of Fabry disease using a fluorometric assay on dried blood spots: An alternative methodology Eur J Med Genet 2015. https:\/\/doi: https:\/\/doi.org\/10.1016\/ej.ejmg.2015.10.014.","DOI":"10.1016\/ej.ejmg.2015.10.014"},{"key":"1274_CR9","doi-asserted-by":"publisher","first-page":"232640981668573","DOI":"10.1177\/2326409816685735","volume":"5","author":"Marco A. Curiati","year":"2017","unstructured":"Curiati MA, Aranda, CS, Kyosen SO, Varela P, Pereira VG, D\u2019 Almeida V, Pesquero JB, Martins AM. The Challenge of Diagnosis and Indication for Treatment in Fabry Disease. J Inborn Errors Metab Screen 2017. https:\/\/doi.org\/https:\/\/doi.org\/10.1177\/2326409816685735.","journal-title":"Journal of Inborn Errors of Metabolism and Screening"},{"issue":"1","key":"1274_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/gm13","volume":"1","author":"Peter D Stenson","year":"2009","unstructured":"Stenson PD, Mort M, Ball EV, Howells K, Phillips AD, Thomas NS, Cooper DN. The human gene mutation database: 2008 update. Genome Med 2009. https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/gm13.","journal-title":"Genome Medicine"},{"issue":"1","key":"1274_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1746-1596-5-65","volume":"5","author":"Karen B M\u00fcller","year":"2010","unstructured":"Muller KB, Rodrigues MDB, Pereira VG, Martins AM, D\u2019Almeida V. Reference values for lysosomal enzyme activities using dried blood spots samples \u2013 a Brazilian experience. Diagn Pathol 2010. https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/1746-1596-5-65.","journal-title":"Diagnostic Pathology"},{"key":"1274_CR12","doi-asserted-by":"publisher","unstructured":"Varela P, Mastroianni Kirsztajn, G, Ferrer H, Aranda C, Wallbach K, Mata GF et al. Functional characterization and pharmacological evaluation of a novel GLA missense mutation found in a severely affected Fabry disease family. Nephron. 2019. https:\/\/doi.org\/https:\/\/doi.org\/10.1159\/000503998.","DOI":"10.1159\/000503998"},{"issue":"1-2","key":"1274_CR13","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.ymgme.2016.11.082","volume":"120","author":"Robert J Desnick","year":"2017","unstructured":"Desnick RJ, Chen R, Srinivasan R, Doheny DO, Bishop DF. The Fabry disease genotype-phenotype database (dbFGP): an international expert consortium. Mol.Genet.Metab. 2017. https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/j.ymgme.2016.11.082.","journal-title":"Molecular Genetics and Metabolism"},{"issue":"7616","key":"1274_CR14","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"Monkol Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O'Donnell-Luria AH et al. Analysis of protein-coding genetic variation in 60,706 humans. Nat.2016. https:\/\/doi.org\/https:\/\/doi.org\/10.1038\/nature19057 .","journal-title":"Nature"},{"key":"1274_CR15","doi-asserted-by":"publisher","unstructured":"Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR. A global reference for human genetic variation. Nat. 2015. https:\/\/doi.org\/https:\/\/doi.org\/10.1038\/nature15393.","DOI":"10.1038\/nature15393"},{"issue":"7","key":"1274_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/humu.23220","volume":"38","author":"Michel Satya Naslavsky","year":"2017","unstructured":"Naslavsky MS, Yamamoto GL, de Almeida TF, Ezquina SAM, Sunaga DY, Pho N, Bozoklian D, Sandberg TOM, Brito LA, Lazar M, Bernardo DV, Amaro E Jr, Duarte YAO, Lebr\u00e3o ML, Passos-Bueno MR, Zatz M. Exomic variants of an elderly cohort of Brazilians in the ABraOM database. Hum Mutat 2017. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/humu.23220.","journal-title":"Human Mutation"},{"issue":"9","key":"1274_CR17","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/nar\/gkp215","volume":"37","author":"Fran\u00e7ois-Olivier Desmet","year":"2009","unstructured":"Desmet FO, Hamroun D, Lalande M, Collod-Beround G, Claustre M, Beround C. Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acid Res 2009. https:\/\/doi.org\/https:\/\/doi.org\/10.1093\/nar\/gkp215.","journal-title":"Nucleic Acids Research"},{"key":"1274_CR18","doi-asserted-by":"publisher","unstructured":"Gelfman S, Wang Q, McSweeney KM, Ren Z, La Carpia F, Halvorsen M, Schoch K, Ratzon F, Heinzen EL, Boland MJ, Petrovski S, Goldstein DB. Annotating pathogenic non-coding variants in genic regions. Nat Commun 2017. https:\/\/doi.org\/https:\/\/doi.org\/10.1038\/s41467-017-00141-2.","DOI":"10.1038\/s41467-017-00141-2"},{"issue":"1","key":"1274_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","volume":"359","author":"Sang-Hoon Shin","year":"2007","unstructured":"Shin SH, Murray GJ, Kluepfel-Stahl S, Cooney AM, Quirk JM, Schiffmann R, Brady RO, Kaneski CR. Screening for pharmacological chaperones in Fabry disease. Biochem Biophys Res Commun. 2007. https:\/\/doi.org\/10.1016\/j.bbrc.2007.05.082","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"8","key":"1274_CR20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/humu.21530","volume":"32","author":"Xiaoyang Wu","year":"2011","unstructured":"Wu X, Katz E., Della Valle MC, Mascioli K, Flanagan, et al. A pharmacogenetic approach to identify mutant forms of \u03b1-galactosidase A that respond to a pharmacological chaperone for Fabry disease. Human mutation, 2011. https:\/\/doi.org\/10.1002\/humu.21530.","journal-title":"Human Mutation"},{"issue":"2","key":"1274_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/humu.9520","volume":"29","author":"Masaaki Shimotori","year":"2008","unstructured":"Shimotori M, Maruyama H, Nakamura G, Suyama T, Sakamoto F, Itoh M, et al. Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone. Hum Mutat. 2008. https:\/\/doi.org\/10.1002\/humu.9520","journal-title":"Human Mutation"},{"issue":"1\u20132","key":"1274_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","volume":"308","author":"NA Chamoles","year":"2001","unstructured":"Chamoles NA, Blanco M. Gaggioli. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta. 2001;308(1\u20132):195\u20136. 11432396.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"1274_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gene.2013.05.050","volume":"527","author":"Ilyas Okur","year":"2013","unstructured":"Okur I, Ezgu F, Biberoglu G. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation. Gene 15. 2013. doi: https:\/\/doi.org\/10.1016\/j.gene.2013.05.050.","journal-title":"Gene"},{"issue":"2","key":"1274_CR24","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.gene.2013.11.101","volume":"536","author":"Cristina D. Castilhos","year":"2014","unstructured":"Castilhos CD, Mezzalira J, Goldim MP, Daitx VV, Garcia Cda S, Andrade CV, Breier AC, C\u00e9 J, Mello AS, Coelho JC. Determination of the lysosomal hydrolase activity in blood collected on filter paper, an alternative to screen high risk populations. Gene. 2014. https:\/\/doi: https:\/\/doi.org\/10.1016\/j.gene.2013.11.101.","journal-title":"Gene"},{"issue":"11","key":"1274_CR25","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1373\/clinchem.2004.037937","volume":"50","author":"Maria Fuller","year":"2004","unstructured":"Fuller M, Lovejoy M, Brooks DA, Harkin ML, Hopwood JJ, Meikle PJ. Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease. Clin Chen 2004. https:\/\/doi:https:\/\/doi.org\/10.1373\/clinchem.2004.037937.","journal-title":"Clinical Chemistry"},{"key":"1274_CR26","doi-asserted-by":"publisher","unstructured":"Lukacs Z, Hartung R, Beck M, Mengel E. Direct comparison of enzyme measurements from dried blood and leukocytes from male and female Fabry disease patients. J. Inherit Metab Dis. 2007. https:\/\/doi::https:\/\/doi.org\/10.1007\/s10545-007-0679-7.","DOI":"10.1007\/s10545-007-0679-7"},{"issue":"1","key":"1274_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","volume":"51","author":"L van der Tol","year":"2013","unstructured":"Van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, Hollak CE. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. J Med Genet 2014. https:\/\/doi.org\/https:\/\/doi.org\/10.1136\/jmedgenet-2013-101857.","journal-title":"Journal of Medical Genetics"},{"issue":"3","key":"1274_CR28","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1399-0004.2011.01689.x","volume":"81","author":"L Ferri","year":"2011","unstructured":"Ferri L, Guido C, la Marca G, Malvagia S, Cavicchi C, Fiumara A, Barone R, Parini R, Antuzzi D, Feliciani C, Zampetti A, Manna R, Giglio S, Della Valle CM, Wu X, Valenzano KJ, Benjamin R, Donati MA, Guerrini R, Genuardi M, Morrone A. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene. Clin Genet 2012. https:\/\/doi.org\/https:\/\/doi.org\/10.1111\/j.1399-0004.2011.01689.x.","journal-title":"Clinical Genetics"},{"issue":"4","key":"1274_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1468-1331.2010.03227.x","volume":"18","author":"C. Tanislav","year":"2010","unstructured":"Tanislav C, Kaps M, Rolfs A, Bottcher T, Lackner K, Paschke E. Frequency of Fabry disease in patients with small-fibre neuropathy of unknown aetiology: a pilot study. Eur J Neurol2011. https:\/\/doi.org\/https:\/\/doi.org\/10.1111\/j.1468-1331.2010.03227.x.","journal-title":"European Journal of Neurology"},{"key":"1274_CR30","doi-asserted-by":"publisher","unstructured":"Pisani A, Imbriaco M, Zizzo C, Albeggiani G, Colomba P, Alessandro R. A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case report. BMC Cardiovasc Disord 2012. https:\/\/doi.org\/https:\/\/doi.org\/10.1186\/1471-2261-12-39.","DOI":"10.1186\/1471-2261-12-39"},{"issue":"S2","key":"1274_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10545-008-0818-9","volume":"31","author":"J. P. Oliveira","year":"2008","unstructured":"Oliveira JP, Ferreira S, Barcel\u00f3 J, Gaspar P, Carvalho F, S\u00e1 Miranda MC, M\u00e5nsson JE. Effect of single-nucleotide polymorphisms of the 5\u2032 untranslated region of the human \u03b1-galactosidase gene on enzyme activity, and their frequencies in Portuguese caucasians. J Inherit Metab Dis 2008. https:\/\/doi.org\/https:\/\/doi.org\/10.1007\/s10545-008-0818-9.","journal-title":"Journal of Inherited Metabolic Disease"},{"key":"1274_CR32","doi-asserted-by":"publisher","unstructured":"Gervas-Arruga J, Cebolla J, Irun P, Perez-Lopez J, Plaza L, Roche J et al. Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the \u03b1-galactosidase a (GLA) gene. BMC Genet 2015. https:\/\/doi: https:\/\/doi.org\/10.1186\/s12863-015.0267-z.","DOI":"10.1186\/s12863-015.0267-z"},{"key":"1274_CR33","doi-asserted-by":"publisher","unstructured":"Vieitez I, Souto-Rodriguez O, Fernandez-Mosquera L, San Millan B, Teijeira S, Fernandez-Martin J et al. Fabry disease in the Spanish population: observational study with detection of 77 patients. Orphanet of rare diseases 2018. https:\/\/doi:https:\/\/doi.org\/10.1186\/s13023-018-0792-8.","DOI":"10.1186\/s13023-018-0792-8"},{"issue":"2","key":"1274_CR34","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","volume":"114","author":"S Ferreira","year":"2015","unstructured":"Ferreira S, Ortiz A, Germain DP, Viana-Baptista M, Caldeira-Gomes A, Camprecios M, Fenollar-Cort\u00e9s M, Gallegos-Villalobos \u00c1, Garcia D, Garc\u00eda-Robles JA, Egido J, Guti\u00e9rrez-Rivas E, Herrero JA, Mas S, Oancea R, P\u00e9res P, Salazar-Mart\u00edn LM, Solera-Garcia J, Alves H, Garman SC, Oliveira JP. The alpha-galactosidase a p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. Mol Genet Metab. 2015 Feb;114(2):248\u201358.","journal-title":"Mol Genet Metab"},{"key":"1274_CR35","doi-asserted-by":"crossref","unstructured":"Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003 Nov;80(3):307\u2013314.Pubmed PMID:1468097.","DOI":"10.1016\/S1096-7192(03)00136-7"},{"issue":"4","key":"1274_CR36","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"Elfrida R. Benjamin","year":"2016","unstructured":"Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, Germain DP, Giugliani R, Hughes D, Schiffmann R, Wilcox WR, Desnick RJ, Kirk J, Barth J, Barlow C, Valenzano KJ, Castelli J, Lockhart DJ. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet. Med. 2017. https:\/\/doi.org\/https:\/\/doi.org\/10.1038\/gim.2016.122.","journal-title":"Genetics in Medicine"},{"issue":"6","key":"1274_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/humu.10275","volume":"22","author":"Makiko Yasuda","year":"2003","unstructured":"Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ. Fabry disease: characterization of alpha-galactosidase a double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 2003. https:\/\/doi.org\/https:\/\/doi.org\/10.1002\/humu.10275.","journal-title":"Human Mutation"},{"issue":"8","key":"1274_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/00365513.2017.1390782","volume":"77","author":"Lis Hasholt","year":"2017","unstructured":"Hasholt L, Ballegaard M, Bundgaard H, Christiansen M, Law I, Lund AM et al. The D313Y variant in the GLA gene - no evidence of a pathogenic role in Fabry disease. Scand J Clin Lab Invest. 2017. Htpps:\/\/doi: https:\/\/doi.org\/10.1080\/00365513.2017.1390782.","journal-title":"Scandinavian Journal of Clinical and Laboratory Investigation"},{"key":"1274_CR39","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/8904_2012_154","volume-title":"JIMD Reports","author":"Markus Niemann","year":"2012","unstructured":"Niemann M, Rolfs A, Giese A, Mascher H, Breunig F, Ertl G, Wanner C, Weidemann F. Lyso-Gb3 indicates that the alpha-Galactosidase a mutation D313Y is not clinically relevant for Fabry disease. JIMD Rep 2013. https:\/\/doi: https:\/\/doi.org\/10.1007\/8904_2012_154."},{"issue":"1","key":"1274_CR40","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"Marco Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ. High incidence of later-onset fabry disease revealed by newborn screening Am J Hum Genet 2006. https:\/\/doi: https:\/\/doi.org\/10.1086\/504601.","journal-title":"The American Journal of Human Genetics"},{"issue":"6","key":"1274_CR41","first-page":"1186","volume":"53","author":"CM Eng","year":"1993","unstructured":"Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the alpha-galactosidase a gene that cause Fabry disease. Am J Hum Genet. 1993;53(6):1186\u201397.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"1274_CR42","doi-asserted-by":"publisher","first-page":"e1003632","DOI":"10.1371\/journal.pgen.1003632","volume":"9","author":"Jan Lukas","year":"2013","unstructured":"Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, Lackner KJ, Meyer W, Wree P, Saviouk V, Rolfs A. Functional characterization of alpha-galactosidase a mutation as a basis for a new classification system in fabry disease. PLoS Genet 2013. https:\/\/doi.org\/https:\/\/doi.org\/10.1371\/journal.pgen.1003632.","journal-title":"PLoS Genetics"},{"issue":"1","key":"1274_CR43","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/humu.22910","volume":"37","author":"Jan Lukas","year":"2015","unstructured":"Lukas J, Scalia S, Eichler S, Pockrandt AM, Dehn N, Cozma C et al. Functional and Clinical Consequences of Novel \u03b1-Galactosidase A Mutations in Fabry Diseas. Hum Mut. 2015. https:\/\/doi.org\/10.1002\/humu.22910.","journal-title":"Human Mutation"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1274-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1274-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1274-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:30:58Z","timestamp":1611793858000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1274-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1274-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]},"assertion":[{"value":"18 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained from all individuals included in the study. The Research Ethics Committee of the Federal University of S\u00e3o Paulo, Brazil approved this protocol (0585\/07 and 0354\/18). All procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2013.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest and confirm independence from the sponsors. The sponsors have not influenced the content of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}